A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib.
10.3779/j.issn.1009-3419.2025.106.25
- Author:
Yunfei WANG
1
;
Wen ZHAO
1
;
Chuang YANG
1
;
Rongyu ZHANG
1
;
Chengjun WANG
1
;
Chunyan HAN
2
;
Jisheng LI
1
Author Information
1. Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China.
2. Department of Radiotherapy
Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.
- Publication Type:English Abstract
- Keywords:
BRAF mutation;
Dabrafenib;
Lung neoplasms;
Targeted therapy;
Trametinib
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Imidazoles/administration & dosage*;
Lung Neoplasms/pathology*;
Mutation;
Neoplasm Metastasis;
Oximes/administration & dosage*;
Proto-Oncogene Mas;
Proto-Oncogene Proteins B-raf/genetics*;
Pyridones/administration & dosage*;
Pyrimidinones/administration & dosage*
- From:
Chinese Journal of Lung Cancer
2025;28(8):638-643
- CountryChina
- Language:Chinese
-
Abstract:
The v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene is one of the most critical proto-oncogenes and functions as a key regulator in the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway. The incidence of BRAF mutations in non-small cell lung cancer (NSCLC) patients ranges from 1.5% to 5.5%, with BRAF V600 mutations accounting for approximately 30%-50% of all BRAF mutations, among which BRAF V600E represents the most prevalent mutation type. Currently, the combination of Dabrafenib and Trametinib has been recommended as first-line therapy for BRAF V600-mutant NSCLC by multiple domestic and international guidelines including National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO), and Chinese Society of Clinical Oncology (CSCO). However, there are no clear targeted treatment recommendations for BRAF non-V600 mutations. Although case reports suggest that Dabrafenib combined with Trametinib may be effective for patients with BRAF non-V600 mutations, the efficacy and safety require further validation due to limited sample size and lack of large-scale clinical trial data. This article reports a case of NSCLC with a rare BRAF insertion and deletion mutation that responded well to the treatment of Dabrafenib in combination with Trametinib, aiming to enhance clinicians' understanding of such NSCLC cases with extremely rare mutation and provide a reference for future treatment strategies.
.
